Immuni T inception was not fortuitous.

After a PhD training in experimental medicine at McGill University and several years of research in academic settings, I was lucky enough to be able to migrate to the private sector where I first acted as CSO of a biotech company developing new compounds for cancer treatments. 

After successful discovery steps I was able to initiate clinical studies with a selected new molecule : di-bromo rhodamine 123 as an ex vivo anti-cancer treatment in autologous or allogeneic bone marrow and PBMC transfer settings. It would specifically eliminate cells with cancerous behavior. This experimental readiness and expertise was put to use through the inception of a new contract research organization: Immuni T in the late 90’s. Since then we never looked back and our efforts at providing support to biotherapeutics developers have concentrated on providing primary human cell tests systems for results that are meaningful and that reduce at the maximum the possibility of failure down the line in clinical phase 3 and phase 4 deployment.
Overall at Immuni T we have time after time not only respected our sponsors projects timelines, but also cared about the integrity of data and transparency of our operations as our main goal is helping patients by improving their quality of life.